Castillo Felipe, Morales Constanza, Spralja Biserka, Díaz-Schmidt Joaquín, Iruretagoyena Mirentxu, Ernst Daniel
Laboratorio Clínico, Clínica Alemana de Santiago, Vitacura, Chile.
Laboratorio Anatomía Patológica, Clínica Alemana de Santiago, Vitacura, Chile.
Cytometry B Clin Cytom. 2024 Jan;106(1):64-73. doi: 10.1002/cyto.b.22147. Epub 2023 Nov 27.
The diagnosis of T-cell non-Hodgkin lymphomas (NHL) is challenging. The development of a monoclonal antibody specific for T-cell receptor β constant region 1 (TRBC1) provides an alternative to discriminate clonal T cells. The aim of this study was to evaluate the diagnostic potential of an anti-TRBC1 mAb for the identification of T-NHL.
We performed a cross-sectional diagnostic analytic study of samples tested for lymphoma. All samples sent for lymphoma screening were first evaluated using the standard Euroflow LST, to which a second additional custom-designed T-cell clonality assessment tube was added CD45/TRBC1/CD2/CD7/CD4/TCRγδ/CD3. Flow cytometry reports were compared with morphological and molecular tests.
Fifty-nine patient samples were evaluated. Within the T-cell population, cut-off percentages in the CD4+ cells were from 29.4 to 54.6% and from 23.9 to 52.1% in CD8+ cells. Cut-off ratios in CD4+ T cells were from 0.33 to 1.1, and in CD8+ cells between 0.22 and 1.0. Using predefined normal cut-off values, 18 of 59 (30.5%) samples showed a restricted expression of TRBC1. A final diagnosis of a T-NHL was confirmed clinically and/or by histopathological studies in 15 of the 18 cases (83.3%). There were no cases of T-NHL by morphology/IHC with normal TRBC1 expression. Non-neoplastic patient samples behaved between predefined TRBC1 cut-off values.
Expression of TRBC1 provides a robust method for T-cell clonality assessment, with very high sensitivity and good correlation with complementary methods. TRBC1 can be integrated into routine lymphoma screening strategies via flow cytometry.
T细胞非霍奇金淋巴瘤（NHL）的诊断具有挑战性。一种针对T细胞受体β恒定区1（TRBC1）的单克隆抗体的开发为鉴别克隆性T细胞提供了一种替代方法。本研究的目的是评估抗TRBC1单克隆抗体在T细胞非霍奇金淋巴瘤识别中的诊断潜力。
我们对检测淋巴瘤的样本进行了横断面诊断分析研究。所有送检进行淋巴瘤筛查的样本首先使用标准的欧洲流式细胞术淋巴瘤筛查检测（Euroflow LST）进行评估，并在此基础上增加了一个定制设计的用于T细胞克隆性评估的检测管，即CD45/TRBC1/CD2/CD7/CD4/TCRγδ/CD3。将流式细胞术报告与形态学和分子检测结果进行比较。
共评估了59例患者样本。在T细胞群体中，CD4⁺细胞的截断百分比为29.4%至54.6%，CD8⁺细胞为23.9%至52.1%。CD4⁺T细胞的截断比值为0.33至1.1，CD8⁺细胞为0.22至1.0。使用预先定义的正常截断值，59个样本中有18个（30.5%）显示TRBC1表达受限。18例中的15例（83.3%）经临床和/或组织病理学研究最终确诊为T细胞非霍奇金淋巴瘤。形态学/免疫组化显示TRBC1表达正常的病例中没有T细胞非霍奇金淋巴瘤。非肿瘤患者样本的表现介于预先定义的TRBC1截断值之间。
TRBC1的表达为T细胞克隆性评估提供了一种可靠的方法，具有很高的敏感性，且与补充方法具有良好的相关性。TRBC1可通过流式细胞术纳入常规淋巴瘤筛查策略。
